Canada · Delayed Price · Currency is CAD Knight Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Record H1 2026 results with CAD 293M revenue and strong EBITDA growth driven by 17 launches. Guidance raised for 2026, expecting at least 20% revenue growth and 15% EBITDA margin, with continued portfolio expansion and stable cash flows supporting future growth.
-
Record Q1 2026 revenues and adjusted EBITDA were driven by portfolio expansion, strong promoted product growth, and multiple new launches. Fiscal 2026 guidance was raised, supported by robust cash flow, a strengthened balance sheet, and continued focus on acquisitions.
-
Record revenues and EBITDA were achieved in 2025, driven by acquisitions and product launches. All director nominees and auditors were approved, with a strong focus on growth in Canada and Latin America and disciplined capital allocation.
Fiscal Year 2025
-
Record 2025 revenue of CAD 452 million (+24% YoY) and adjusted EBITDA of CAD 73 million were driven by strong product launches and portfolio expansion. Guidance for 2026 targets CAD 490–510 million in revenue with continued investment in launches and infrastructure.
-
A six-product portfolio was acquired for CAD 25.4M upfront plus up to CAD 15.75M in milestones, with immediate revenue recognition and minimal integration needs. Growth assets are expected to drive portfolio expansion from 2026, offsetting declines in mature products.
Fiscal Year 2024
-
Record 2024 revenues of over CAD 365 million were driven by promoted products and pipeline expansion, with oncology and infectious diseases portfolios showing strong growth. 2025 guidance anticipates further revenue gains but lower EBITDA margin due to launch investments and the Paladin acquisition.
-
Record revenues and strong portfolio growth were achieved despite currency headwinds and increased operating expenses. Guidance for 2024 is maintained, with new product launches and a robust pipeline expected to drive future growth.
-
Record H1 2024 revenues and Adjusted EBITDA were driven by strong oncology and specialty growth, while infectious disease sales declined due to lower AMBISOME orders. Raised 2024 revenue guidance reflects currency improvements and accelerated pipeline investments.